Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety Study of Pomaglumetad Methionil in Schizophrenia
NCT01487083Phase 3Terminated
- Sponsor
- Denovo Biopharma
- Start
- Dec 2011
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of pomaglumetad methionil in schizophrenia, sponsored by Denovo Biopharma. Started Dec 2011; status: terminated.
02
Drugs
pomaglumetad methionil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01487083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01487083.